Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 17 mas receptor

Vijayakumar Sukumaran, Punniyakoti T. Veeraveedu, Arun Lakshmanan, Narasimman Gurusamy, Ken'Ichi Yamaguchi, Meilei Ma, Kenji Suzuki, Makoto Kodama, Kenichi Watanabe

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Angiotensin converting enzyme-2 (ACE-2) is a monocarboxypeptidase that metabolises angiotensin (ANG)-II into angiotensin 17 (ANG 1-7), thereby functioning as a negative regulator of the renin-angiotensin system. We investigated whether treatment with ANG-II type 1 receptor blocker, olmesartan medoxomil is associated with the attenuation of cardiac myosin-induced dilated cardiomyopathy (DCM) through recently established new axis of ACE-2/ANG 17 mas receptor. DCM was elicited in Lewis rats by immunisation with cardiac myosin, and 28 days after immunisation, the surviving Lewis rats were divided into two groups and treated with either olmesartan medoxomil (10 mg/kg/day) or vehicle. Myocardial protein and mRNA levels of ACE-2, ANG 17 mas receptor were upregulated in the olmesartan-treated group compared with those of vehicle-treated DCM rats. In contrast, Olmesartan treatment effectively suppressed the myocardial protein and mRNA expressions of inflammatory markers in comparison to the vehicle-treated DCM rats. Olmesartan treatment significantly reduced fibrosis, hypertrophy and their marker molecules (OPN, CTGF, ANP and GATA-4, respectively), as well as matrix metalloproteinases compared with those of vehicle-treated DCM rats. Enhanced myocardial protein levels of phospho-p38 MAPK, phospho-JNK and phospho MAPKAPK-2 in the vehicle-treated DCM rats were prevented by olmesartan treatment. In addition, olmesartan treatment significantly lowered the protein expressions (Nitrotyrosine, p47phox and p67phox) and superoxide radical production compared with those of vehicle-treated DCM rats. Our present study might serve as a new therapeutic target of DCM in cardiovascular diseases and cardiac myosin-induced DCM via the modulation of ACE-2/ANG 1-7 mas receptor axis in rats with DCM after myosin-immunisation.

Original languageEnglish
Pages (from-to)850-860
Number of pages11
JournalFree Radical Research
Volume46
Issue number7
DOIs
Publication statusPublished - 1 Jul 2012
Externally publishedYes

Fingerprint

Cardiac Myosins
Angiotensins
Dilated Cardiomyopathy
Rats
Modulation
Immunization
Therapeutics
Proteins
Angiotensin II Type 1 Receptor Blockers
Messenger RNA
angiotensin converting enzyme 2
Olmesartan Medoxomil
Atrial Natriuretic Factor
p38 Mitogen-Activated Protein Kinases
Myosins
Matrix Metalloproteinases
Renin
Superoxides
Angiotensin II
Renin-Angiotensin System

Keywords

  • Angiotensin 1-7
  • Angiotensin converting enzyme-2
  • Dilated cardiomyopathy
  • Inflammation
  • Olmesartan medoxomil
  • Oxidative stress

ASJC Scopus subject areas

  • Biochemistry

Cite this

Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 17 mas receptor. / Sukumaran, Vijayakumar; Veeraveedu, Punniyakoti T.; Lakshmanan, Arun; Gurusamy, Narasimman; Yamaguchi, Ken'Ichi; Ma, Meilei; Suzuki, Kenji; Kodama, Makoto; Watanabe, Kenichi.

In: Free Radical Research, Vol. 46, No. 7, 01.07.2012, p. 850-860.

Research output: Contribution to journalArticle

Sukumaran, Vijayakumar ; Veeraveedu, Punniyakoti T. ; Lakshmanan, Arun ; Gurusamy, Narasimman ; Yamaguchi, Ken'Ichi ; Ma, Meilei ; Suzuki, Kenji ; Kodama, Makoto ; Watanabe, Kenichi. / Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 17 mas receptor. In: Free Radical Research. 2012 ; Vol. 46, No. 7. pp. 850-860.
@article{83fcb0f499cd4c89a31388b0c183b1da,
title = "Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 17 mas receptor",
abstract = "Angiotensin converting enzyme-2 (ACE-2) is a monocarboxypeptidase that metabolises angiotensin (ANG)-II into angiotensin 17 (ANG 1-7), thereby functioning as a negative regulator of the renin-angiotensin system. We investigated whether treatment with ANG-II type 1 receptor blocker, olmesartan medoxomil is associated with the attenuation of cardiac myosin-induced dilated cardiomyopathy (DCM) through recently established new axis of ACE-2/ANG 17 mas receptor. DCM was elicited in Lewis rats by immunisation with cardiac myosin, and 28 days after immunisation, the surviving Lewis rats were divided into two groups and treated with either olmesartan medoxomil (10 mg/kg/day) or vehicle. Myocardial protein and mRNA levels of ACE-2, ANG 17 mas receptor were upregulated in the olmesartan-treated group compared with those of vehicle-treated DCM rats. In contrast, Olmesartan treatment effectively suppressed the myocardial protein and mRNA expressions of inflammatory markers in comparison to the vehicle-treated DCM rats. Olmesartan treatment significantly reduced fibrosis, hypertrophy and their marker molecules (OPN, CTGF, ANP and GATA-4, respectively), as well as matrix metalloproteinases compared with those of vehicle-treated DCM rats. Enhanced myocardial protein levels of phospho-p38 MAPK, phospho-JNK and phospho MAPKAPK-2 in the vehicle-treated DCM rats were prevented by olmesartan treatment. In addition, olmesartan treatment significantly lowered the protein expressions (Nitrotyrosine, p47phox and p67phox) and superoxide radical production compared with those of vehicle-treated DCM rats. Our present study might serve as a new therapeutic target of DCM in cardiovascular diseases and cardiac myosin-induced DCM via the modulation of ACE-2/ANG 1-7 mas receptor axis in rats with DCM after myosin-immunisation.",
keywords = "Angiotensin 1-7, Angiotensin converting enzyme-2, Dilated cardiomyopathy, Inflammation, Olmesartan medoxomil, Oxidative stress",
author = "Vijayakumar Sukumaran and Veeraveedu, {Punniyakoti T.} and Arun Lakshmanan and Narasimman Gurusamy and Ken'Ichi Yamaguchi and Meilei Ma and Kenji Suzuki and Makoto Kodama and Kenichi Watanabe",
year = "2012",
month = "7",
day = "1",
doi = "10.3109/10715762.2012.684878",
language = "English",
volume = "46",
pages = "850--860",
journal = "Free Radical Research",
issn = "1071-5762",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 17 mas receptor

AU - Sukumaran, Vijayakumar

AU - Veeraveedu, Punniyakoti T.

AU - Lakshmanan, Arun

AU - Gurusamy, Narasimman

AU - Yamaguchi, Ken'Ichi

AU - Ma, Meilei

AU - Suzuki, Kenji

AU - Kodama, Makoto

AU - Watanabe, Kenichi

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Angiotensin converting enzyme-2 (ACE-2) is a monocarboxypeptidase that metabolises angiotensin (ANG)-II into angiotensin 17 (ANG 1-7), thereby functioning as a negative regulator of the renin-angiotensin system. We investigated whether treatment with ANG-II type 1 receptor blocker, olmesartan medoxomil is associated with the attenuation of cardiac myosin-induced dilated cardiomyopathy (DCM) through recently established new axis of ACE-2/ANG 17 mas receptor. DCM was elicited in Lewis rats by immunisation with cardiac myosin, and 28 days after immunisation, the surviving Lewis rats were divided into two groups and treated with either olmesartan medoxomil (10 mg/kg/day) or vehicle. Myocardial protein and mRNA levels of ACE-2, ANG 17 mas receptor were upregulated in the olmesartan-treated group compared with those of vehicle-treated DCM rats. In contrast, Olmesartan treatment effectively suppressed the myocardial protein and mRNA expressions of inflammatory markers in comparison to the vehicle-treated DCM rats. Olmesartan treatment significantly reduced fibrosis, hypertrophy and their marker molecules (OPN, CTGF, ANP and GATA-4, respectively), as well as matrix metalloproteinases compared with those of vehicle-treated DCM rats. Enhanced myocardial protein levels of phospho-p38 MAPK, phospho-JNK and phospho MAPKAPK-2 in the vehicle-treated DCM rats were prevented by olmesartan treatment. In addition, olmesartan treatment significantly lowered the protein expressions (Nitrotyrosine, p47phox and p67phox) and superoxide radical production compared with those of vehicle-treated DCM rats. Our present study might serve as a new therapeutic target of DCM in cardiovascular diseases and cardiac myosin-induced DCM via the modulation of ACE-2/ANG 1-7 mas receptor axis in rats with DCM after myosin-immunisation.

AB - Angiotensin converting enzyme-2 (ACE-2) is a monocarboxypeptidase that metabolises angiotensin (ANG)-II into angiotensin 17 (ANG 1-7), thereby functioning as a negative regulator of the renin-angiotensin system. We investigated whether treatment with ANG-II type 1 receptor blocker, olmesartan medoxomil is associated with the attenuation of cardiac myosin-induced dilated cardiomyopathy (DCM) through recently established new axis of ACE-2/ANG 17 mas receptor. DCM was elicited in Lewis rats by immunisation with cardiac myosin, and 28 days after immunisation, the surviving Lewis rats were divided into two groups and treated with either olmesartan medoxomil (10 mg/kg/day) or vehicle. Myocardial protein and mRNA levels of ACE-2, ANG 17 mas receptor were upregulated in the olmesartan-treated group compared with those of vehicle-treated DCM rats. In contrast, Olmesartan treatment effectively suppressed the myocardial protein and mRNA expressions of inflammatory markers in comparison to the vehicle-treated DCM rats. Olmesartan treatment significantly reduced fibrosis, hypertrophy and their marker molecules (OPN, CTGF, ANP and GATA-4, respectively), as well as matrix metalloproteinases compared with those of vehicle-treated DCM rats. Enhanced myocardial protein levels of phospho-p38 MAPK, phospho-JNK and phospho MAPKAPK-2 in the vehicle-treated DCM rats were prevented by olmesartan treatment. In addition, olmesartan treatment significantly lowered the protein expressions (Nitrotyrosine, p47phox and p67phox) and superoxide radical production compared with those of vehicle-treated DCM rats. Our present study might serve as a new therapeutic target of DCM in cardiovascular diseases and cardiac myosin-induced DCM via the modulation of ACE-2/ANG 1-7 mas receptor axis in rats with DCM after myosin-immunisation.

KW - Angiotensin 1-7

KW - Angiotensin converting enzyme-2

KW - Dilated cardiomyopathy

KW - Inflammation

KW - Olmesartan medoxomil

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84862175607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862175607&partnerID=8YFLogxK

U2 - 10.3109/10715762.2012.684878

DO - 10.3109/10715762.2012.684878

M3 - Article

C2 - 22497476

AN - SCOPUS:84862175607

VL - 46

SP - 850

EP - 860

JO - Free Radical Research

JF - Free Radical Research

SN - 1071-5762

IS - 7

ER -